Showing 6041-6050 of 6777 results for "".
- AAD, Other Major Medical Associations Support March For Sciencehttps://practicaldermatology.com/news/aad-other-major-medical-associations-support-march-for-science/2458214/The American Academy of Dermatology is joining up with many leading organizations in support of the March for Science and its nonpartisan call for the appreciation of scientific evidence, education, and investment. There are close to
- Topical Cannabinoids May Soothe Itchy Skinhttps://practicaldermatology.com/news/topical-cannabinoids-may-soothe-itchy-skin/2458218/Cannabinoids contain anti-inflammatory properties that may make them useful in the treatment of a wide-range of skin diseases including eczema, psoriasis, atopic and contact dermatitis, according to researchers at the University of Colorado Anschutz Medical Campus. The new study app
- ThermiGen, an Almirall company, Names Vladimir Paul-Blanc President & General Managerhttps://practicaldermatology.com/news/thermigen-an-almirall-company-names-vladimir-paul-blanc-president-general-manager/2458219/Vladimir Paul-Blanc has been named President & General Manager of ThermiGen, LLC, starting May 1. He will report directly to the Executive Vice-president of Commercial Strategy of Almirall, Alfonso Ugarte, and he will be responsible for all general management responsibilities for the Thermi b
- Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategyhttps://practicaldermatology.com/news/allergan-names-daphne-karydas-as-senior-vice-president-of-global-investor-relations-strategy/2458224/Daphne Karydas is Allergan’s new Senior Vice President of Global Investor Relations and Strategy, effective April 17, 2017. In this role, Ms. Karydas will lead the Company's engagement with the investment community, and will work with
- Phase 4 Studies of Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefithttps://practicaldermatology.com/news/phase-4-studies-of-restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit/2458226/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Merz Taps Bob Rhatigan as New President, CEOhttps://practicaldermatology.com/news/merz-taps-bob-rhatigan-as-new-president-ceo/2458229/Allergan vet Bob Rhatigan is the new President and Chief Executive Officer (CEO) of Merz North America, and Patrick Urban will serve as Chief Commercial Officer, effective immediately. In his new role, Mr. Rhatigan will assume responsibility for Merz&rsq
- Novan Forms New Advisory Council Focused on Nitric Oxide Technologies in Dermatologyhttps://practicaldermatology.com/news/novan-forms-new-advisory-council-focused-on-nitric-oxide-technologies-in-dermatology/2458228/Novan, Inc. has formed an Advisory Council comprised of key opinion leaders with broad expertise in dermatology. These leading physicians will provide medical advice and drug-development insight to the Company’s senior leadership team and board of directors. The Advisory Council will
- Positive Results Announced from SebuDerm Gel Study in Treatment of Seborrheic Dermatitishttps://practicaldermatology.com/news/positive-results-announced-from-sebuderm-gel-study-in-treatment-of-seborrheic-dermatitis/2458237/The results of a clinical study evaluating the impact of Sonoma Pharmaceuticals, Inc.'s SebuDerm (topical hypochlorous acid) gel in the treatment of mild to moderate facial and scalp seborrheic dermatitis were presented at the 13th Annual Maui Dermatology Conference in Maui, HI.
- Heliocare Spotlights Improved Formulation: Vegan, Gluten-free, and Dye-freehttps://practicaldermatology.com/news/heliocare-spotlights-improved-formulation-vegan-gluten-free-and-dye-free/2458243/Heliocare Daily Use Antioxidant Formula, a clinically proven, natural dietary supplement with antioxidant effects on the skin, has been updated to be vegan, gluten-free, and free of artificial dyes. The once-daily capsules from Ferndale Healthcare, have been recommended by dermatologists fo
- RepliCel's Baldness Cure Performs Well In First In-Human Trialhttps://practicaldermatology.com/news/replicels-baldness-cure-performs-well-in-first-in-human-trial/2458246/The first in-human study of RepliCel Life Sciences Inc’s investigational baldness cure, RCH-01, confirms the therapy’s safety and demonstrates strong efficacy signals, the company reports. The autologous cell therapy involves culturing a person’s own dermal sheath cup ce